Scarica l'app Stockscreener
2.85
7.14%
0.19
Dopo l'orario di chiusura:
2.84
-0.01
-0.35%
Precedente Chiudi:
$2.66
Aprire:
$2.67
Volume 24 ore:
519.85K
Relative Volume:
1.04
Capitalizzazione di mercato:
$55.54M
Reddito:
-
Utile/perdita netta:
$-40.94M
Rapporto P/E:
-0.7422
EPS:
-3.84
Flusso di cassa netto:
$-22.97M
1 W Prestazione:
+1.42%
1M Prestazione:
-6.86%
6M Prestazione:
-42.07%
1 anno Prestazione:
-73.54%
Intervallo 1D:
$2.62
$2.89
Intervallo di 1 settimana:
$2.52
$2.89
Portata 52W:
$1.11
$11.29
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Confronta ANVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.85 | 51.83M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors - TipRanks
Is Annovis Bio Inc. a good long term investmentFree Consultation - Autocar Professional
What analysts say about Annovis Bio Inc. stockFree Capital Allocation Plans - Autocar Professional
What drives Annovis Bio Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
Annovis Bio Inc. Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference - MSN
What risks could impact Annovis Bio Inc. stock performanceCapital Growth Picks - Newser
Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study - TipRanks
Why Annovis Bio Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - newser.com
What makes Annovis Bio Inc. stock price move sharplyFree Popular Stock Recommendations - Newser
How Annovis Bio Inc. stock performs during market volatilityCapital Growth Picks - newser.com
Annovis Bio's Volatility Trap: Why Risky Bets and Biotech Headwinds Spell Caution for Investors - AInvest
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR.com
Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors? - TipRanks
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025 - citybuzz -
Annovis Bio Plunges 10.13% on Analyst Price Target Cut - AInvest
Annovis Bio (ANVS) Stock Jumps Over 16% in Market Trading | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Approves Board Elections and Auditor Appointment - TipRanks
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window - FinancialContent
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - The Manila Times
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):